



## Standard BioTools to Participate in Upcoming Investor Conferences

October 31, 2024

SOUTH SAN FRANCISCO, Calif., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that its management team will participate in the following investor conferences in the month of November:

- **UBS Global Healthcare Conference on November 12<sup>th</sup>, 2024**

President and CEO, Michael Egholm, PhD, will participate in a corporate presentation on Tuesday, November 12, 2024, at 1:15 p.m. PT

- **Jefferies London Healthcare Conference on November 19<sup>th</sup> – 21<sup>st</sup>, 2024**

President and CEO, Michael Egholm, PhD, will participate in a corporate presentation on Tuesday, November 19, 2024, at 8:30 a.m. GMT

Available presentations will be webcast live and available on the Investor Relations page of the Company's website at [Events & Presentations](#). A recording will be archived and available on the Standard BioTools Investor Relations page at [investors.standardbio.com](#).

### About Standard BioTools Inc.

Standard BioTools Inc. (Nasdaq: LAB), the parent company of SomaLogic Inc. and previously known as Fluidigm Corporation, has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop medicines faster and better. As a leading solutions provider, the company provides reliable and repeatable insights in health and disease using its proprietary mass cytometry and microfluidics technologies, which help transform scientific discoveries into better patient outcomes. Standard BioTools works with leading academic, government, pharmaceutical, biotechnology, plant and animal research and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology and immunotherapy. Learn more at [standardbio.com](#) or connect with us on X, Facebook®, LinkedIn, and YouTube™.

For Research Use Only. Not for use in diagnostic procedures.

Limited Use Label License and other terms may apply: [standardbio.com/legal/salesterms](#).

Patent and License Information: [standardbio.com/legal/notices](#).

Trademarks: [standardbio.com/legal/trademarks](#). Any other trademarks are the sole property of their respective owners. ©2024 Standard BioTools Inc. (f.k.a. Fluidigm Corporation). All rights reserved.

### Investor Contact

David Holmes  
Gilmartin Group LLC  
[ir@standardbio.com](mailto:ir@standardbio.com)



Source: Standard BioTools Inc.